Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

Moderna, Inc. (MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus responsible for the 2020 pandemic. The regulatory filing is based on guidance from the FDA last week, whereby the regulatory body advised eminent vaccine manufacturers like Moderna, Novavax (NVAX) and Pfizer (PFE) to update their respective COVID-19 vaccines to a monovalent (single strain) JN.1 compositio ...